[go: up one dir, main page]

AR093787A1 - Derivados de aminociclobutano, su metodo de preparacion y su uso como medicamentos - Google Patents

Derivados de aminociclobutano, su metodo de preparacion y su uso como medicamentos

Info

Publication number
AR093787A1
AR093787A1 ARP130104484A ARP130104484A AR093787A1 AR 093787 A1 AR093787 A1 AR 093787A1 AR P130104484 A ARP130104484 A AR P130104484A AR P130104484 A ARP130104484 A AR P130104484A AR 093787 A1 AR093787 A1 AR 093787A1
Authority
AR
Argentina
Prior art keywords
trans
amino
diethyl
cyclobutancarboxamide
atom
Prior art date
Application number
ARP130104484A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR093787A1 publication Critical patent/AR093787A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/14Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a derivados de aminociclobutano particularmente como antagonistas de los receptores de NMDA, su aplicación en terapia para seres humanos y su método de preparación. Estos compuestos corresponden a la fórmula general (1), donde: X¹ representa un átomo de hidrógeno o átomo de flúor; X² es un átomo de hidrógeno o átomo de flúor o átomo de cloro; R¹ representa un átomo de hidrógeno o átomo de flúor o átomo de cloro o un grupo metilo o grupo metoxi o grupo ciano; R² representa independientemente o en forma conjunta un grupo metilo o un grupo etilo. Reivindicación 3: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 ó 2, caracterizado porque se selecciona entre los siguientes compuestos: trans-3-amino-N,N-dietil-1-fenilciclobutancarboxamida, trans-3-amino-N,N-dimetil-1-fenilciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(2-fluorofenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(3-metoxifenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(3-fluorofenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(3-clorofenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(3-metilfenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(3-cianofenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(2-flúor-3-clorofenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(2,5-difluorofenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(3,5-difluorofenil)-ciclobutancarboxamida, trans-3-amino-N,N-dietil-1-(3,5-diclorofenil)-ciclobutancarboxamida.
ARP130104484A 2012-12-04 2013-12-04 Derivados de aminociclobutano, su metodo de preparacion y su uso como medicamentos AR093787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1261621A FR2998892B1 (fr) 2012-12-04 2012-12-04 Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments

Publications (1)

Publication Number Publication Date
AR093787A1 true AR093787A1 (es) 2015-06-24

Family

ID=48128432

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104484A AR093787A1 (es) 2012-12-04 2013-12-04 Derivados de aminociclobutano, su metodo de preparacion y su uso como medicamentos

Country Status (30)

Country Link
US (2) US9469601B2 (es)
EP (1) EP2928861B1 (es)
JP (1) JP6391586B2 (es)
KR (1) KR102221928B1 (es)
CN (2) CN106957285B (es)
AR (1) AR093787A1 (es)
AU (1) AU2013354133B2 (es)
BR (1) BR112015012752B1 (es)
CA (1) CA2893216C (es)
CY (1) CY1118841T1 (es)
DK (1) DK2928861T3 (es)
ES (1) ES2621896T3 (es)
FR (1) FR2998892B1 (es)
HR (1) HRP20170564T1 (es)
IL (1) IL239146A (es)
LT (1) LT2928861T (es)
MA (1) MA38229B1 (es)
MX (1) MX364556B (es)
MY (1) MY179886A (es)
NZ (1) NZ709572A (es)
PL (1) PL2928861T3 (es)
PT (1) PT2928861T (es)
RS (1) RS55916B1 (es)
RU (1) RU2655919C2 (es)
SA (1) SA515360518B1 (es)
SI (1) SI2928861T1 (es)
TN (1) TN2015000240A1 (es)
TW (1) TWI603947B (es)
UA (1) UA114017C2 (es)
WO (1) WO2014086825A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202003519A (zh) 2018-03-28 2020-01-16 日商武田藥品工業股份有限公司 雜環化合物及其用途
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
WO2021098732A1 (zh) * 2019-11-18 2021-05-27 江苏恩华药业股份有限公司 一种1',2'-二氢-3'h-螺[环丁烷1,4'-异喹啉]-3'-酮衍生物及其应用
CN115353489A (zh) * 2021-05-17 2022-11-18 苏州恩华生物医药科技有限公司 一种氘代酰胺类衍生物及其应用
CN116425677A (zh) * 2022-01-11 2023-07-14 苏州恩华生物医药科技有限公司 氨基环丁烷衍生物的盐、其晶型及其制备方法和应用
CN116715632B (zh) * 2022-03-07 2025-09-30 苏州恩华生物医药科技有限公司 螺[环丁烷1,4′-异喹啉]酮类衍生物顺反异构体的制备方法
CN119143701B (zh) * 2023-06-16 2025-11-18 北京大学 一种[2.1.1]桥环内酯单体和可回收聚酯及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133924A (en) * 1960-05-31 1964-05-19 Bristol Myers Co Amino-substituted cyclobutane carboxamides
FR2581059B1 (fr) * 1985-04-25 1988-04-22 Pf Medicament Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
EP0747348A4 (en) * 1994-02-22 1999-07-07 Asahi Chemical Ind AMINOALKYLCYCLOPROPAN DERIVATIVES
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
ES2241055T3 (es) 1996-08-23 2005-10-16 Endo Pharmaceuticals Inc Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico.
BR9812162A (pt) 1997-09-08 2000-07-18 Warner Lambert Co Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
US6118017A (en) * 1998-04-14 2000-09-12 Smithkline Beecham Corporation Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one
BR9912827A (pt) 1998-07-16 2001-05-02 Sloan Kettering Inst Cancer Composições tópicas compreendendo um analgésico opióide e um antagonista de nmda
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US7820688B2 (en) 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
AU2003210486B2 (en) 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US7709472B2 (en) 2005-01-25 2010-05-04 Glaxo Group Limited Antibacterial agents
US8212043B2 (en) 2007-02-01 2012-07-03 Janssen R&D Ireland Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV
AU2008245662A1 (en) * 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
CA2697739A1 (en) 2007-08-27 2009-03-05 Wyeth Llc Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect
HRP20120944T1 (hr) 2007-11-28 2012-12-31 Astellas Pharma Inc. Kondenzirani spoj indana
US8722714B2 (en) 2008-01-16 2014-05-13 The Honk Kong University of Science and Technology Oxazolidine derivatives as NMDA antagonists
EP2334176A4 (en) 2008-09-27 2012-05-02 Taraxos Inc TOPICAL FORMULATIONS FOR THE TREATMENT OF NERVE DISEASES
TW201026667A (en) 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
FR2943666B1 (fr) 2009-03-31 2011-04-15 Commissariat Energie Atomique Metallophore derive de nicotianamine et ses procedes de fabrication
FR2944011B1 (fr) * 2009-04-03 2011-05-20 Pf Medicament Derives d'aminocyclobutane ou d'aminocyclobutene, leur procede de preparation et leur utilisation a titre de medicaments.
CA2759951C (en) * 2009-05-07 2017-05-02 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
FR2946535B1 (fr) 2009-06-10 2011-09-09 Neureva Composition comprenant une molecule favorisant l'interaction neurone-glie, notamment pour prevenir la formation de la cicatrice gliale et induire la regeneration neurale.
TWI544923B (zh) 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物

Also Published As

Publication number Publication date
EP2928861A1 (fr) 2015-10-14
US20170065543A1 (en) 2017-03-09
CN106957285B (zh) 2019-05-03
BR112015012752A2 (pt) 2017-07-11
DK2928861T3 (en) 2017-04-24
CA2893216A1 (fr) 2014-06-12
TN2015000240A1 (fr) 2016-10-03
HRP20170564T1 (hr) 2017-06-16
MX2015006686A (es) 2015-08-10
MA38229A1 (fr) 2016-01-29
ES2621896T3 (es) 2017-07-05
US9687459B2 (en) 2017-06-27
FR2998892B1 (fr) 2015-01-02
RS55916B1 (sr) 2017-09-29
FR2998892A1 (fr) 2014-06-06
PL2928861T3 (pl) 2017-08-31
MA38229B1 (fr) 2016-09-30
IL239146A (en) 2017-06-29
RU2015126104A (ru) 2017-01-10
KR102221928B1 (ko) 2021-03-02
BR112015012752B1 (pt) 2020-10-27
RU2655919C2 (ru) 2018-05-30
TWI603947B (zh) 2017-11-01
UA114017C2 (xx) 2017-04-10
JP6391586B2 (ja) 2018-09-19
PT2928861T (pt) 2017-04-24
EP2928861B1 (fr) 2017-01-11
SA515360518B1 (ar) 2017-05-17
AU2013354133A1 (en) 2015-07-23
CN104854083A (zh) 2015-08-19
CN106957285A (zh) 2017-07-18
IL239146A0 (en) 2015-07-30
HK1212968A1 (zh) 2016-06-24
MY179886A (en) 2020-11-18
US20150315132A1 (en) 2015-11-05
AU2013354133B2 (en) 2017-07-06
LT2928861T (lt) 2017-04-25
KR20150091163A (ko) 2015-08-07
CN104854083B (zh) 2017-05-24
MX364556B (es) 2019-04-30
JP2016502555A (ja) 2016-01-28
SI2928861T1 (sl) 2017-05-31
CY1118841T1 (el) 2018-01-10
CA2893216C (fr) 2021-01-26
TW201427930A (zh) 2014-07-16
US9469601B2 (en) 2016-10-18
WO2014086825A1 (fr) 2014-06-12
NZ709572A (en) 2019-02-22

Similar Documents

Publication Publication Date Title
AR093787A1 (es) Derivados de aminociclobutano, su metodo de preparacion y su uso como medicamentos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
DOP2015000274A (es) Compuestos químicos
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
MX373786B (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
PE20150734A1 (es) Inhibidores de glucosilceramida sintasa
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY31065A1 (es) Heterociclos ciclicos
CR20160098A (es) Polimorfo de los inhibidores de la syk
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
CY1118848T1 (el) Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
PE20151754A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor

Legal Events

Date Code Title Description
FC Refusal